| Literature DB >> 34670873 |
Yumei Chen1, Chiyu Ma1,2, Lixiong Liu3, Jingquan He1, Chengxin Zhu1, Fengping Zheng1, Weier Dai4, Xiaoping Hong3, Dongzhou Liu3, Donge Tang1, Yong Dai1,2.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease described by joint destruction, synovitis and pannus formation. The gut microbiota acts as an environmental factor that plays an important role in RA, but little research regarding the etiopathogenic mechanisms of the microbiome in RA has been carried out. We used an integrated approach of 16S rRNA gene sequencing and ultrahigh-performance liquid chromatography-mass spectrometry-based metabolomics to analyze the structure and diversity of the intestinal flora and metabolites of the gut microbiota in RA patients compared with healthy subjects. In this study, α-diversity analysis of the gut microbiota showed that there was no significant difference between the healthy control (HC) and RA groups. However, β-diversity analysis showed that there was a significant difference between the two groups. Further analysis of alteration of the gut microbiota revealed that at the phylum level, the relative abundance of p_Bacteroidetes was significantly decreased in the RA group, while that of Verrucomicrobia and Proteobacteria was significantly increased in the RA group. At the genus level, Bacteroides, Faecalibacterium and some probiotics were decreased in the RA group, while 97 genera, including Lactobacillus, Streptococcus and Akkermansia, were increased in the RA group. Seventy-four differentially abundant metabolites were identified between the HC and RA groups, and we identified two potential biomarkers (9,12-octadecadiynoic acid and 10Z-nonadecenoic acid) in RA.Entities:
Keywords: biomarkers; gut microbiota; metabolites; rheumatoid arthritis
Mesh:
Substances:
Year: 2021 PMID: 34670873 PMCID: PMC8580343 DOI: 10.18632/aging.203641
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
The clinical index of healthy controls (HC) and RA patients (RA).
|
|
|
|
| Age (Years) | 44.1±1.9070 | 58.9±2.5930 |
| Triglyceride (mol/L) | 1.505±0.2373 | 1.289±0.1599 |
| Total cholesterol (mol/L) | 4.555±0.1494 | 4.429±0.1777 |
| Creatinine (μmol/L) | 75.43±3.2420 | 61.36±2.7270 |
| Serum albumin (g/L) | 44.76±0.5605 | 34.24±0.9881 |
| HDL cholesterol (mol/L) | 1.467±0.0597 | 1.199±0.0822 |
| LDL cholesterol (mol/L) | 2.472±0.1149 | 2.659±0.1306 |
| Globulin (g/L) | 26.56±0.7955 | 34.38±1.4650 |
| Urea nitrogen (mmol/L) | 4.78±0.2252 | 5.378±0.4498 |
| Uric acid (μmol/L) | 339.5±15.6500 | 297.1±14.8400 |
| Total bilirubin | 14.54±1.1490 | 7.117±0.6790 |
Values are mean ± standard deviation; HDL, high density lipoprotein; LDL, low density lipoprotein.
Figure 1The species abundance and diversity. (A) The rank abundance curve of HC and RA group. (B) The OTUs (97% similarity) of HC and RA group. (C) The principal coordinate analysis score (PcoA) plots base on the relative abundance of OTUs, unweighted unifrac PcoA plots between HC group and RA group. HC group showed in red dots, RA group showed in blue dots. (D) Species α-diversity differences between the HC group and RA group (ACE, Chao1, Shannon and Simpson index).
Figure 2The species abundance at phylum level. (A) Relative abundance of gut microbiota in every samples at phylum level, n=30 for HC group and n=29 for RA group. (B, C) Component proportion of gut microbiota at phylum level in HC and RA group.
Figure 3The species abundance at genus level. (A) Relative abundance of gut microbiota in every samples at the genus level, n=30 for HC group and n=29 for RA group. (B, C) Component proportion of gut microbiota at the genus level in HC and RA group.
Figure 4Line discriminant analysis (LDA) effect size analysis. (A) Cladogram indicating the phylogenetic distribution of differential gut microbiota between the HC or RA group. (B) The differential gut microbiota with LDA Score >4 between the HC and RA groups.
Figure 5Significantly changed metabolites heatmap in feces samples between HC and RA group.
Figure 6Identification of potential biomarkers. (A) The pathway analysis of differential metabolites. (B) Correlation analysis of differential gut microbiota and differential metabolites between HC and RA group. The ROC curve of biomarker analysis for 9,12-Octadecadiynoic Acid (C) and 10Z-nonadecenoic acid (D).